Loading clinical trials...
Loading clinical trials...
Phase 4, Randomized, 52-Week Study To Evaluate Two Assessment Tools To Predict Treatment Success At 52 Weeks Based On A Treatment Decision At Week 12 In Subjects With Moderate To Severe Rheumatoid Arthritis Receiving Cimzia
Conditions
Interventions
Certolizumab Pegol (CZP)
Locations
110
United States
137
Birmingham, Alabama, United States
166
Huntsville, Alabama, United States
165
Peoria, Arizona, United States
216
Tucson, Arizona, United States
168
Hot Springs, Arkansas, United States
241
Jonesboro, Arkansas, United States
Start Date
November 1, 2010
Primary Completion Date
October 1, 2012
Completion Date
December 1, 2012
Last Updated
July 31, 2018
NCT07536529
NCT06329401
NCT07048197
NCT07484243
NCT06647069
NCT06841562
Lead Sponsor
UCB Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions